Connolly, Mark P <br/><br/>
Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.  [electronic resource] 

 -  Journal of Crohn's & colitis  May 2014 
 - 357-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1876-4479 
<br/><br/><label>Standard No.: </label>10.1016/j.crohns.2013.09.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Colitis, Ulcerative--diagnosis<br/>Cost-Benefit Analysis<br/>Drug Administration Schedule<br/>Gastrointestinal Agents--administration & dosage<br/>Humans<br/>Mesalamine--administration & dosage<br/>Netherlands<br/>Patient Compliance<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Remission Induction<br/>Research Design<br/>Severity of Illness Index